Comparative Pharmacology
Head-to-head clinical analysis: MIVACRON versus MIVACURIUM CHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MIVACRON versus MIVACURIUM CHLORIDE.
MIVACRON vs MIVACURIUM CHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mivacurium is a bis-benzylisoquinoline neuromuscular blocking agent that acts as a competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, leading to muscle paralysis.
Mivacurium chloride is a non-depolarizing neuromuscular blocking agent that competitively binds to nicotinic acetylcholine receptors at the motor end-plate, preventing acetylcholine from binding and thereby inhibiting neuromuscular transmission. It is a mixture of stereoisomers and is rapidly hydrolyzed by plasma cholinesterase.
0.15-0.2 mg/kg IV bolus for intubation; maintenance infusion 9-10 mcg/kg/min
0.15-0.25 mg/kg IV bolus for endotracheal intubation; maintenance infusion: 0.5-1.5 mcg/kg/min IV
None Documented
None Documented
Terminal elimination half-life is approximately 2-3 minutes; clinically, rapid clearance via plasma cholinesterase results in short duration.
Terminal elimination half-life is approximately 2 minutes (range 1-3 minutes) for the initial rapid distribution phase, and the elimination half-life is about 17-20 minutes in patients with normal renal function. Clinically, this short half-life allows for rapid recovery of neuromuscular function.
Primarily renal (approximately 80-90% as unchanged drug and metabolites) and biliary (small fraction, <20% as metabolites).
Primarily renal excretion of unchanged drug and metabolites; approximately 90-95% eliminated via urine, with less than 5% in feces. Minor biliary excretion.
Category C
Category C
Neuromuscular Blocker
Neuromuscular Blocker